It depends Maverick0408, if the DCVax-L clinical trial data is very strong and positive, and it shows a significant increase in overall survival (OS), and it is quickly approved by regulators in the US, UK, Canada, Germany and the rest of the EU, and DCVax-L becomes part of the new standard of care (SOC) to treat GBM patients worldwide.
You do not have to promote and advertise SOC treatments as much as you do other non-SOC alternative / optional treatments. Oncologists worldwide will have to explain to grieving families (and their lawyers) worldwide, why their family members were not treated with DCVax-L.
Market Data 
Markets 
AI
